---
schema_version: "secwatch.filing_event.v1"
accession: "0000019584-21-000011"
form_type: "8-K"
ticker: "CHE"
cik: "0000019584"
company_name: "CHEMED CORP"
filed_at: "2021-07-27T23:59:59+00:00"
generated_at: "2026-06-30T02:17:49.957423+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Chemed Q2 adj. EPS $4.60 (+4.3% YoY); Roto-Rooter revenue +26.1%; full-year guidance raised to $18.20-$18.50

## Summary
- Consolidated revenue $532M (+6.0%); GAAP diluted EPS $3.51 (-29.9%); adjusted diluted EPS $4.60 (+4.3%).
- VITAS net patient revenue $312M (-4.7%); ADC 17,995 (-6.3%); adjusted EBITDA margin ex-Medicare Cap 17.4% (-430bps).
- Roto-Rooter revenue $220M (+26.1%); adjusted EBITDA margin 29.2% (+236bps); residential +23.7%, commercial +31.8%.
- Full-year 2021 adjusted EPS guidance raised to $18.20-$18.50 from prior $17.00-$17.50; no debt, $92M cash.
- Company repurchased 250,000 shares for $122M during Q2; $312M remaining authorization.

## SEC filing metadata
- accession: 0000019584-21-000011
- form_type: 8-K
- ticker: CHE
- cik: 0000019584
- company_name: CHEMED CORP
- filed_at: 2021-07-27T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/19584/000001958421000011/0000019584-21-000011-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/19584/000001958421000011/che-20210727x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000019584-21-000011
- JSON: https://secwatch.observer/filing/0000019584-21-000011.json
- Plain text: https://secwatch.observer/filing/0000019584-21-000011.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.